Our data suggest that patients are less likely to benefit from genotoxic drug-based neoadjuvant chemotherapy if they have breast cancers with high ZEB1 expression, compared with tumors with low ZEB1 expression. The gene discussed is ZEB1; the disease is breast carcinoma.